By replacing adalimumab with biosimilar versions, NHS hospitals will only pay a quarter of the £400m they currently spend each year on the drug. <ClickHere>
NHS England to save £300m after patent expiry of most costly drug
-
Why Climate Change fails?
#climatechange #nature #naturalresources #marketeconomics #globestrategy #greenpeace Exxon Mobil profits are…
-
Michael Porter – Strategy
Professor Michael Porter of Harvard University’s School of Business discusses…
-
Deloitte’s Transfer Pricing practice
Deloitte’s Transfer Pricing practice has prepared the Global Tax Reset…